A Study of AZD0120 in Autoimmune Diseases

Study Summary

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

Conditions

Systemic Sclerosis Idiopathic Inflammatory Myopathies Rheumatoid Arthritis

Interventions / Drugs

AZD0120

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment27 participants

Primary Completion—

Lead SponsorAstraZeneca

Data Retrieved2026-04-11 02:55:19.910815+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.